SCHEMBL3313096

SCHEMBL3313096

CN1C(=O)CC(c2ccccc2)(C(F)(F)F)[C@@]1(C)C(N)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
BACE1 P56817 5/20 0.38
TACR1 P25103 1/20 0.33
NR1I2 O75469 1/20 0.32
RORC P51449 1/20 0.32
DRD2 P14416 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
POLB P06746 1/20 0.32
CYP1A2 P05177 3/20 0.32
CYP2C19 P33261 3/20 0.32
HCAR3 P49019 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
CYP2C9 P11712 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
PAX8 Q06710 1/20 0.32
MCL1 Q07820 1/20 0.32
CYP3A4 P08684 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3312805 0.83 BACE1 (0.35) BACE1NR1I2RORCPOLBCYP1A2
SCHEMBL2913180 0.69 AKR1C1 (0.41) NR1I2RORCSMN1; SMN2
SCHEMBL3306090 0.67 ALDH1A1 (0.38) ALDH1A1BACE1TACR1NR1I2RORC
SCHEMBL6378176 0.64 OPRL1 (0.41) ALDH1A1BACE1CYP2C9LMNA
SCHEMBL6472118 0.63 AKR1C1 (0.38) ALDH1A1TACR1SIGMAR1POLBLMNA
SCHEMBL28487473 0.62 SLC6A4 (0.46) POLBCYP1A2CYP2C19CYP2C9L3MBTL1
SCHEMBL28304679 0.60 AKR1C1 (0.48) POLBCYP2C19CYP2C9L3MBTL1CYP3A4
SCHEMBL12397137 0.60 LMNA (0.50) ALDH1A1CYP2C9LMNA
SCHEMBL5790641 0.59 HSD11B1 (0.39) ALDH1A1LMNASMN1; SMN2
SCHEMBL30980908 0.59 ALDH1A1 (0.38) ALDH1A1BACE1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718693-B2 Receptor antagonists and their methods of use GLAXO GROUP LIMITED (GB) 2010-05-18 US disclosed
WO-2009074518-A1 COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS GLAXO GROUP LIMITED (GB) 2009-06-18 WO disclosed
US-20080009541-A1 Novel Receptor Antagonists and Their Methods of Use GLAXO GROUP LIMITED (GB) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009541-A1 Novel Receptor Antagonists and Their Methods of Use P2RX7, P2RX3, P2RX1 ALDH1A1 2150/4885BACE1 729/4885TACR1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.